Literature DB >> 8490081

Safety of lansoprazole.

D G Colin-Jones1.   

Abstract

The care with which patients are monitored during clinical trials provides an excellent database to assess the tolerability and safety of drugs. Additional information can be obtained from knowledge of the compound itself, its metabolism and its pharmacological action. Other compounds from the same class can highlight areas that need particular study. All these factors have been used to assess the safety of lansoprazole. Lansoprazole has been administered to 4749 subjects and has been well tolerated. Only 1.2% of patients have been withdrawn from trials because of suspected drug-related events but there was no pattern and no relationship to drug dosage. Diarrhoea (3.2%) and headache (4.7%) were the most commonly reported adverse events.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8490081     DOI: 10.1111/j.1365-2036.1993.tb00590.x

Source DB:  PubMed          Journal:  Aliment Pharmacol Ther        ISSN: 0269-2813            Impact factor:   8.171


  11 in total

1.  Lichenoid drug eruption with proton pump inhibitors.

Authors:  J L Bong; T W Lucke; W S Douglas
Journal:  BMJ       Date:  2000-01-29

Review 2.  Pharmacokinetic drug interaction profiles of proton pump inhibitors.

Authors:  Henning Blume; Frank Donath; André Warnke; Barbara S Schug
Journal:  Drug Saf       Date:  2006       Impact factor: 5.606

3.  Long term omeprazole therapy for reflux esophagitis:follow-up in serum gastrin levels,EC cell hyperplasia and neoplasia.

Authors:  Pankaj Singh; Anant Indaram; Ronald Greenberg; Vernu Visvalingam; Simmy Bank
Journal:  World J Gastroenterol       Date:  2000-12       Impact factor: 5.742

4.  Determinants of headache in lansoprazole users in The Netherlands: results from a nested case-control study.

Authors:  Angela A M C Claessens; Eibert R Heerdink; Jacques T H M van Eijk; Cornelis B H W Lamers; Hubert G M Leufkens
Journal:  Drug Saf       Date:  2002       Impact factor: 5.606

Review 5.  Pharmacokinetics, metabolism and interactions of acid pump inhibitors. Focus on omeprazole, lansoprazole and pantoprazole.

Authors:  T Andersson
Journal:  Clin Pharmacokinet       Date:  1996-07       Impact factor: 6.447

Review 6.  Trends in the management of gastro-oesophageal reflux disease.

Authors:  J M Lee; C A O'Morain
Journal:  Postgrad Med J       Date:  1998-03       Impact factor: 2.401

Review 7.  Clinical pharmacokinetics of lansoprazole.

Authors:  B D Landes; J P Petite; B Flouvat
Journal:  Clin Pharmacokinet       Date:  1995-06       Impact factor: 6.447

Review 8.  Lansoprazole. A reappraisal of its pharmacodynamic and pharmacokinetic properties, and its therapeutic efficacy in acid-related disorders.

Authors:  C M Spencer; D Faulds
Journal:  Drugs       Date:  1994-09       Impact factor: 9.546

Review 9.  Pharmacokinetic drug interaction profiles of proton pump inhibitors: an update.

Authors:  Ralph-Steven Wedemeyer; Henning Blume
Journal:  Drug Saf       Date:  2014-04       Impact factor: 5.606

10.  Does lymphocytic colitis always present with normal endoscopic findings?

Authors:  Hye Sun Park; Dong Soo Han; Young Ouk Ro; Chang Soo Eun; Kyo Sang Yoo
Journal:  Gut Liver       Date:  2015-03       Impact factor: 4.519

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.